Janssen Pharmaceutical | Date: 2017-04-05
Janssen Pharmaceutical | Date: 2017-01-04
The present invention is directed to compounds having P2X7 modulating properties. The invention also relates to pharmaceutical compositions comprising these compounds. Methods of making and using these compounds are also within the scope of the invention.
Microfluidics, Janssen Pharmaceutical and NXP Semiconductors | Date: 2017-02-15
The invention relates to a channel for trapping particles to be fed to said channel with a fluid, said channel having a bottom and opposite sidewalls, the sidewalls defining a width of the channel, said channel further comprising:- a first channel part;- a second channel part in fluid through flow connection with said first channel part and downstream of said first channel part;- an elevated structure provided in said channel that divides said channel in said first channel part and said second channel part and for trapping particles in said first channel part;- at least one flow gap provided by said elevated structure for providing said fluid through flow connection between the first channel part and the second channel part for allowing, in use, at least some fluid to flow past said elevated structure into said second channel part while trapping said particles in said first channel part;wherein said elevated structure is substantially U-shaped and has a base extending substantially between the opposite sidewalls of the channel and two legs extending from the base in an upstream direction, wherein at least part of said U-shaped elevated structure defines at least part of a particle trapping area for trapping the particles to be fed to said channel. The invention further relates to a flow cell comprising such a channel. The invention also relates to an assembly comprising such a flow cell and a detection means. The invention also relates to a method for trapping particles in such a channel. And finally, the invention relates to a method for analyzing a sample using such an assembly.
Janssen Pharmaceutical | Date: 2017-01-04
The present invention is directed to novel opioid receptor modulators of Formula: (I). The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may be ameliorated or treated by the modulation of opioid receptors.
Janssen Pharmaceutical | Date: 2017-02-15
The present invention relates to substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine derivatives of formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as ROS 1 inhibitors. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
Janssen Pharmaceutical | Date: 2017-01-11
The present invention is directed to bicyclic pyrrole derivatives of formula (I), pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GPR120. More particularly, the compounds of the present invention are agonists of GPR120, useful in the treatment of, such as for example. Type II diabetes mellitus.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: SC1-PM-22-2016 | Award Amount: 15.59M | Year: 2016
ZIKAlliance is a multidisciplinary project with a global One Health approach, built: on a multi-centric network of clinical cohorts in the Caribbean, Central & South America; research sites in countries where the virus has been or is currently circulating (Africa, Asia, Polynesia) or at risk for emergence (Reunion Island); a strong network of European and Brazilian clinical & basic research institutions; and multiple interfaces with other scientific and public health programmes. ZIKAlliance will addrees three key objectives relating to (i) impact of Zika virus (ZIKV) infection during pregnancy and short & medium term effects on newborns, (ii) associated natural history of ZIKV infection in humans and their environment in the context of other circulating arboviruses and (iii) building the overall capacity for preparedness research for future epidemic threats in Latin America & the Caribbean. The project will take advantage of large standardised clinical cohorts of pregnant women and febrile patients in regions of Latin America and the Caribbean were the virus is circulating, expanding a preexisting network established by the IDAMS EU project. I will also benefit of a very strong expertise in basic and environmental sciences, with access to both field work and sophisticated technological infrastructures to characterise virus replication and physiopathology mechanisms. To meet its 3 key objectives, the scientific project has been organised in 9 work packages, with WP2/3 dedicated to clinical research (cohorts, clinical biology, epidemiology & modeling), WP3/4 to basic research (virology & antivirals, pathophysiology & animal models), WP5/6 to environmental research (animal reservoirs, vectors & vector control) , WP7/8 to social sciences & communication, and WP9 to management. The broad consortium set-up allow gathering the necessary expertise for an actual interdisciplinary approach, and operating in a range of countries with contrasting ZIKV epidemiological status.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: NMBP-01-2016 | Award Amount: 7.59M | Year: 2017
Objectives The H-CCAT project designs, upscales and shapes hybrid catalysts for the C-H functionalization of aromatic compounds. These solid catalysts will possess better recoverability, higher turnover numbers and better selectivity than current homogeneous catalysts for these reactions. The solid catalysts are applied at demonstration scale in the step-economical production of arylated or alkenylated aromatics, yielding motifs of active pharmaceutical ingredients. Methodology We will design heterogeneous hybrid catalysts featuring deactivation-resistant active sites, based on N-heterocyclic carbenes (NHCs) or diimine ligands and active metal ions. Via efficient, one-step protocols based on self-assembly, these sites will be embedded in robust porous hybrid materials like hybrid silica or metal-organic frameworks. Deactivation or metal aggregation will be prevented by site isolation or by efficient metal reoxidation (for the oxidative alkenylations). Metal leaching is precluded by using strong bonds between metals and embedded ligands like NHCs. Flow protocols will be designed to maximize the turnover numbers. Catalyst synthesis will be scaled up to kg scale, using efficient one-step protocols, minimizing use of solvents or waste formation. Soft shaping methods, e.g. spray drying, will preserve porosity and activity of the hybrid solids. A demonstration is conducted at minipilot scale at the J&J site (Belgium), allowing LCA analysis, techno-economic assessment and elaboration of the business plan. Relevance to work program The catalysts feature new, deactivation resistant active sites; their TOF/TON is maximized by an appropriate porous structure which even can be swelling. Catalysts are produced using innovative one-step protocols to form porous hybrid catalysts as powders or even immediately as shaped objects. The molecules targeted have strong biological and pharmaceutical relevance; they target diseases like influenza, cancer or HIV (case study: Rilpivirine).
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: EINFRA-5-2015 | Award Amount: 4.94M | Year: 2016
This Centre of Excellence will advance the role of computationally based modelling and simulation within biomedicine. Three related user communities lie at the heart of the CoE: academic, industrial and clinical researchers who all wish to build, develop and extend such capabilities in line with the increasing power of high performance computers. Three distinct exemplar research areas will be pursued: cardiovascular, molecularly-based and neuro-musculoskeletal medicine. Predictive computational biomedicine involves applications that are comprised of multiple components, arranged as far as possible into automated workflows in which data is taken, from an individual patient, processed, and combined into a model which produces predicted health outcomes. Many of the models are multiscale, requiring the coupling of two or more high performance codes. Computational biomedicine holds out the prospect of predicting the effect of personalised medical treatments and interventions ahead of carrying them out, with all the ensuing benefits. Indeed, in some cases, it is already doing so today. The CoE presents a powerful consortium of partners and has an outward facing nature and will actively train, disseminate and engage with these user communities across Europe and beyond. Because this field is new and growing rapidly, it offers numerous innovative opportunities. There are three SMEs and three enterprises within the project, as well as eight associate partners drawn from across the biomedical sector, who are fully aware of the vast potential of HPC in this domain. We shall work with them to advance the exploitation of HPC and will engage closely with medical professionals through our partner hospitals in order to establish modeling and simulation as an integral part of clinical decision making. Our CoE is thus user-driven, integrated, multidisciplinary, and distributed; presenting a vision that is in line with the Work Programme.
Agency: European Commission | Branch: H2020 | Program: MSCA-ITN-ETN | Phase: MSCA-ITN-2015-ETN | Award Amount: 3.85M | Year: 2015
Given an overwhelming increase of dementia costs and an aging population, there is an urgent need for finding novel therapies for Alzheimer Disease (AD). We are, however, facing a large number of failed clinical trials and a retraction of the nervous system R&D programmes from several big pharmaceutical companies. Increased collaboration between academia and the private sector is required to overcome this challenge. The Synaptic Dysfunction in Alzheimer Disease (SyDAD) project will significantly contribute to this approach by training a new generation of researchers with experience and full understanding of the requirements of academia, pharmaceutical companies, the clinics and the society. The research programme will focus on synaptic dysfunction, the main connection point between pathology and cognitive decline in AD. Given the complementary expertise, SyDAD will have excellent opportunities to delineate the cross-talk between different pathways underlying synaptic dysfunction in AD and to identify novel pharmaceutical targets. For future implementation of the research findings into clinical trials, a drug discovery platform will be elaborated, utilising the industrial and clinical expertise in the network. The early-stage researchers (ESRs) will be trained in this environment and provided with a mind-set of future commercial and clinical utilisation of their research findings. Apart from the innovative and collaborative approach of the research programme, the ESRs will also be provided with a training programme where cutting-edge methodology, innovation and transferable skills are key components. The trained ESRs will have excellent intersectoral and interdisciplinary career opportunities and will, together with the SyDAD partners, provide a solid ground to tackle one of the major societal challenges of our century: Finding therapies to decrease the suffering and economic burden of AD patients.